Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
With a market cap of 875.95B, Eli Lilly(LLY) trades at $927.99. The stock has a price-to-earnings ratio of 40.39 and currently yields dividends of 67.2%.
During the trading session on 2026-04-20, Eli Lilly(LLY) shares reached a daily high of $927.99 and a low of $923.00. At a current price of $927.99, the stock is +0.5% higher than the low and still 0.0% under the high.
Trading volume for Eli Lilly(LLY) stock has reached 14.77K, versus its average volume of 2.55M.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.
LLY News
Biotech and Pharma Eli Lilly Closes in on a $2 Billion Deal. What It Means for the Stock. In this article LLY Eli Lilly's deal for Kelonia Therapeutics could co...
(RTTNews) - Eli Lilly (LLY) is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, according to the Wall Street Journal, citing people f...
Eli Lilly (LLY) is in advanced discussions to acquire Kelonia Therapeutics for over $2B in a deal that could come as soon as Monday, Lauren Thomas of The Wall S...
Analyst ratings
83%
of 35 ratingsMore LLY News
Eli Lilly (LLY) is in advanced negotiations to acquire Kelonia Therapeutics in a transaction valued at more than $2 billion, The Wall Street Journal reported Su...
Cancer drugs are an important part of Lilly’s portfolio. AJ Mast/Bloomberg News Eli Lilly LLY 2.55 %increase; green up pointing triangle is in advanced talks t...
Eli Lilly (LLY) is back in focus after reporting positive Phase 3 ACHIEVE-4 results for its oral GLP-1 drug Foundayo, easing recent safety concerns and supporti...
Key Points Eli Lilly's GLP-1 drugs are growing fast, but competition in the new drug niche is heating up. Although the stock has performed very well over the...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper...
Key Points Eli Lilly has been a growth beast, coming off an impressive year in which its revenue rose by 45%. Viking Therapeutics has an exciting GLP-1 drug i...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.